Healthcare technology provider Medtronic has agreed to purchase SPR Therapeutics for an upfront cash payment of nearly $650 million. This SPR Therapeutics acquisition is structured to broaden clinical care options for individuals requiring chronic pain management. By moving to take over all outstanding equity in the specialized company, Medtronic will secure enhanced access to temporary, percutaneous peripheral nerve stimulation therapies.
The SPR Therapeutics acquisition represents a calculated strategy to enhance the buyer’s portfolio in the peripheral nerve stimulation sector. The integration of these targeted therapies aims to expand the existing range of neuromodulation solutions offered to healthcare professionals and patients.
The acquired system delivers a 60-day, short-term intervention tailored for chronic pain management, functioning effectively without the need for permanent implants. Incorporating this medical device allows Medtronic to actively support healthcare providers in deploying earlier interventions within the established chronic pain care pathway.
Real-world clinical data underscores the viability of the technology. In the largest retrospective review of real-world outcomes encompassing over 6,100 patients, more than 71% reported significant pain relief or an enhanced quality of life following treatment with the 60-day peripheral nerve stimulation system.
Maria Bennett, president and CEO of SPR Therapeutics, commented on the agreement: “Guided by our credo to advancing meaningful, patient-centred innovation in pain medicine, our agreement with Medtronic marks a pivotal step forward. Together, we will reach more patients, helping them find relief earlier in their care journey to reclaim their lives and get back to what matters most.”
Completion of the transaction remains subject to customary closing conditions and standard regulatory reviews. Medtronic expects to finalize the deal during the first half of its fiscal year 2027, which commenced on April 25, 2026. The acquisition is projected to have a minor impact on adjusted earnings per share during fiscal year 2027, with a neutral to positive effect anticipated in subsequent reporting periods. Until the transaction officially closes, both organizations will continue to operate as independent entities.
In parallel operational developments earlier this month, Medtronic received the CE mark for its VitalFlow Transport Frame Air and Ground (AG). This new hardware functions as an accessory to the VitalFlow extracorporeal membrane oxygenation (ECMO) system, further complementing the company’s broader pipeline of critical care and neuromodulation solutions.
